Mitsubishi Tanabe Pharma Corporation (MTPC), announced that Edaravone was approved by the National Medical Products Administration (NMPA) for an intravenous treatment for amyotrophic lateral sclerosis (ALS).
Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. that is MTPC’s R&D subsidiary in China has filed it, and Tianjin Tanabe Seiyaku Co., Ltd. that is MTPC’s manufacture and sales subsidiary in China will market Edaravone. Edaravone was approved for use as a treatment for ALS in Japan, June 2015, followed by South Korea, U.S., Canada, and Switzerland. With China’s approval, Edaravone has been approved by six countries.
ALS is an idiopathic neurodegenerative disease in which motor neurons selectively degenerate and vanish. Muscle strength declines throughout the entire body, including the limb, facial, and respiratory muscles, and muscular atrophy progress. While the cause for the majority of cases is not well understood but may involve genetic and environmental factors. It is one of the most well-known neuromuscular diseases, affecting approximately two in 100,000 people worldwide. As many as 20,000 or 30,000 people are estimated to be affected by ALS in China.
Edaravone is a free-radical scavenger that was discovered by MTPC. It is thought that edaravone has the effect of scavenging free radicals, which increase in ALS, protecting motor neurons from oxidative stress, and delaying the decline in muscle strength and the progress of muscular atrophy.
MTPC will strive to deliver edaravone to patients fighting against ALS all over the world.